Liquidia Corporation
LQDA
Rang în acțiuni
#4848
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Preț acțiune
$34.12
Capitalizare de piață
$3.05B
Schimbare (1 zi)
-0.67%
Schimbare (1 an)
51.78%
Țară
US
Tranzacționează Liquidia Corporation (LQDA)
Categorie
Healthcare
EPS pentru Liquidia Corporation (LQDA)
EPS la data de June 2026 TTM: $1.57
Conform celor mai recente rapoarte financiare și prețului acțiunilor Liquidia Corporation, EPS-ul actual al companiei (TTM) este $1.57. La sfârșitul anului 2023, compania avea un EPS de $-1.21 o creștere față de EPS-ului din 2022, care a fost de $-0.67.
Istoricul EPS pentru Liquidia Corporation din 2016 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $1.57 | -194.58% |
| 2024 | $-1.66 | 37.19% |
| 2023 | $-1.21 | 80.60% |
| 2022 | $-0.67 | -4.29% |
| 2021 | $-0.70 | -60.23% |
| 2020 | $-1.76 | -29.88% |
| 2019 | $-2.51 | -66.17% |
| 2018 | $-7.42 | 118.24% |
| 2017 | $-3.40 | 82.80% |
| 2016 | $-1.86 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $2.41 | 53.50% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -66.88% |
US
|
